View More Recent Stories
-
Nurix (NRIX) PT Raised to $27 at Oppenheimer
-
Truist Securities Starts Nurix (NRIX) at Buy
-
Nurix (NRIX) PT Raised to $30 at Stifel
-
Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
-
Nurix (NRIX) PT Lowered to $29 at Needham
-
Nurix (NRIX) PT Raised to $27 at RBC Capital
-
Nurix Therapeutics, Inc. (NRIX) Misses Q2 EPS by 8c
-
Nurix (NRIX) PT Raised to $26 at RBC Capital
-
Nurix (NRIX) PT Raised to $26 at H.C. Wainwright
-
Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
-
RBC Capital Reiterates Outperform Rating on Nurix (NRIX)


